AR090557A1 - DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 - Google Patents
DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2Info
- Publication number
- AR090557A1 AR090557A1 ARP130101043A AR090557A1 AR 090557 A1 AR090557 A1 AR 090557A1 AR P130101043 A ARP130101043 A AR P130101043A AR 090557 A1 AR090557 A1 AR 090557A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- haloalkyl
- 6alkyl
- hydroxyalkyl
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicación 1: Un compuesto de la fórmula (1), caracterizado porque X es O ó S; R¹ es hidroxi, halógeno, alquilo C₁₋₆, haloalquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₆, alcoxi C₁₋₆, haloalcoxi C₁₋₆, hidroxialquilo C₁₋₆, ciano, alcoxi C₁₋₆alquilo C₁₋₆, alcoxi C₁₋₆alcoxi C₁₋₆alquilo C₁₋₆, hidroxialcoxi C₁₋₆, hidroxialcoxi C₁₋₆alquilo C₁₋₆, hidroxialquenilo C₂₋₆, alqueniloxi C₂₋₆alquenilo C₂₋₆, haloalcoxi C₁₋₆alquilo C₁₋₆, haloalcoxi C₁₋₆-haloalquilo C₁₋₆, alcoxi C₁₋₆-haloalcoxi C₁₋₆, carboxi, alquil C₁₋₆-(C=O)-, alcoxi C₁₋₆-(C=O)-, alquil C₁₋₆-(C=O)-O-, haloalquil C₁₋₆-(C=O)-, haloalcoxi C₁₋₆-(C=O)-, (R⁶)₂N-, (R⁶)₂N-alquilo C₁₋₆, (R⁶)₂N-(C=O)-, R⁶-(C=O)-N(R⁶)-(C=O)-, R⁶-(O=S=O)-N(R⁶)-(C=O)-, R⁶-(C=O)-N(R⁶)-(O=S=O)-, R⁶-(O=S=O)-N(R⁶)-(O=S=O)-, (R⁶)₂N-N-, (R⁶)N=N-, (R⁶)₂N-O-, (R⁶)O-N(R⁶)-, alquil C₁₋₆-S-, alquenil C₂₋₆-S-alquenilo C₂₋₆, hidroxialquil C₁₋₆-S-, hidroxialquil C₁₋₆-S-alquilo C₁₋₆, alcoxi C₁₋₆alquil C₁₋₆-S-alquilo C₁₋₆, haloalquil C₁₋₆-S-, haloalquil C₁₋₆-S-alquilo C₁₋₆, haloalquil C₁₋₆-S-haloalquilo C₁₋₆, R⁶-(O=S)-, (R⁶)₂N-(O=S)-, R⁶-(O=S=O)-, (R⁶)₂N-(O=S=O)-, fenilo, fenil-O-, heteroarilo, heteroaril-O-, fenil-N(R⁶)-, heteroaril-N(R⁶)-, o heteroarilalquilo C₁₋₆; R² es H, hidroxi, oxo, fluoro, alquilo C₁₋₆, haloalquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆ cicloalquilo C₃₋₆, alcoxi C₁₋₆, haloalcoxi C₁₋₆, hidroxialquilo C₁₋₆, ciano, alcoxi C₁₋₆alquilo C₁₋₆, alcoxi C₁₋₆alcoxi C₁₋₆alquilo C₁₋₆, hidroxialcoxi C₁₋₆, hidroxialcoxi C₁₋₆alquilo C₁₋₆, hidroxialquenilo C₂₋₆, alqueniloxi C₂₋₆alquenilo C₂₋₆, haloalcoxi C₁₋₆alquilo C₁₋₆, haloalcoxi C₁₋₆-haloalquilo C₁₋₆, alcoxi C₁₋₆-haloalcoxi C₁₋₆, carboxi, alquil C₁₋₆-(C=O)-, -alcoxi C₁₋₆-(C=O)-, alquil C₁₋₆-(C=O)-O-, haloalquil C₁₋₆-(C=O)-, haloalcoxi C₁₋₆-(C=O)-, (R⁶)₂N-, (R⁶)₂N-alquilo C₁₋₆, (R⁶)₂N-(C=O)-, R⁶-(C=O)-N(R⁶)-(C=O)-, R⁶-(O=S=O)-N(R⁶)-(C=O)-, R⁶-(C=O)-N(R⁶)-(O=S=O)-, R⁶-(O=S=O)-N(R⁶)-(O=S=O)-, (R⁶)₂N-N-, (R⁶)N=N-, (R⁶)₂N-O-, (R⁶)O=N-, alquil C₁₋₆-S-, alquenil C₂₋₆-S-alquenilo C₂₋₆, hidroxialquil C₁₋₆-S-, hidroxialquil C₁₋₆-S-alquilo C₁₋₆, alcoxi C₁₋₆alquil C₁₋₆-S-alquilo C₁₋₆, haloalquil C₁₋₆-S-, haloalquil C₁₋₆-S-alquilo C₁₋₆, haloalquil C₁₋₆-S-haloalquilo C₁₋₆, R⁶-(O=S)-, (R⁶)₂N-(O=S)-, R⁶-(O=S=O)-, (R⁶)₂N-(O=S=O)-, fenilo, fenil-O-, heteroarilo, heteroaril-O-, fenil-N(R⁶)-, heteroaril-N(R⁶)-, o heteroarilalquilo C₁₋₆; R³ es H, alquilo C₁₋₆, haloalquilo C₁₋₆, alcoxi C₁₋₆, haloalcoxi C₁₋₆, hidroxialquilo C₁₋₆, alcoxi C₁₋₆alquilo C₁₋₆, o cicloalquilo C₃₋₆; R⁴ es H, hidroxi, halógeno, alquilo C₁₋₂, o haloalquilo C₁₋₂; R⁵ es H, hidroxi, halógeno, alquilo C₁₋₆, haloalquilo C₁₋₂, cicloalquilo C₃₋₆, alcoxi C₁₋₆, haloalcoxi C₁₋₆, hidroxialquilo C₁₋₆, fenilo, o heteroarilo; y R⁶ es, independientemente en cada ocurrencia, H, alquilo C₁₋₆, alcoxi C₁₋₆alquilo C₁₋₆, hidroxialquilo C₁₋₆, haloalquilo C₁₋₆ o R⁶ y R⁶ forman, junto con los átomos a los cuales ellos se enlazan, un anillo carbocíclico saturado o insaturado de 4, 5, 6 ó 7 elementos condensado o un anillo heterocíclico saturado o insaturado de 4, 5, 6 ó 7 elementos condensado que contiene 1 ó 2 heteroátomo(s) seleccionados de N, O y S, caracterizado porque dicho anillo carbocíclico o heterocíclico es no sustituido o sustituido con 1 ó 2 sustituyente(s) cada uno siendo independientemente hidroxi, oxo, halógeno, alquilo C₁₋₆, hidroxialquilo C₁₋₆, o haloalquil C₁₋₆-; o R¹ y R² forman, junto con los átomos de carbono en el anillo a los cuales ellos están enlazados, un anillo carbocíclico saturado o insaturado de 4, 5, 6 ó 7 elementos condensado o un anillo heterocíclico saturado o insaturado de 4, 5, 6 ó 7 elementos condensado que contiene 1 ó 2 heteroátomo(s) seleccionados de N, O y S, caracterizado porque dicho anillo carbocíclico o heterocíclico es no sustituido o sustituido con 1 ó 2 sustituyente(s) cada uno siendo independientemente hidroxi, oxo, halógeno, alquilo C₁₋₆, alcoxi C₁₋₆alquilo C₁₋₆, hidroxialquilo C₁₋₆, o haloalquilo C₁₋₆; o R² y R³ forman, junto con los átomos de carbono en el anillo a los cuales ellos están enlazados, un anillo carbocíclico saturado o insaturado de 4, 5, 6 ó 7 elementos condensado o un anillo heterocíclico saturado o insaturado de 4, 5, 6 ó 7 elementos condensado que contiene 1 ó 2 heteroátomo(s) seleccionados de N, O y S, caracterizado porque dicho anillo carbocíclico o heterocíclico es no sustituido o sustituido con 1 ó 2 sustituyente(s) cada uno siendo independientemente hidroxi, oxo, halógeno, alquilo C₁₋₆, alcoxi C₁₋₆alquilo C₁₋₆, hidroxialquilo C₁₋₆, o haloalquilo C₁₋₆; o una sal o éster del mismo aceptable desde el punto de vista farmacéutico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261619109P | 2012-04-02 | 2012-04-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR090557A1 true AR090557A1 (es) | 2014-11-19 |
Family
ID=48224812
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130101043 AR090557A1 (es) | 2012-04-02 | 2013-03-27 | DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 |
Country Status (26)
Country | Link |
---|---|
US (1) | US9249127B2 (es) |
EP (1) | EP2834233B1 (es) |
JP (1) | JP6427096B2 (es) |
KR (1) | KR102104228B1 (es) |
CN (1) | CN104220437B (es) |
AR (1) | AR090557A1 (es) |
AU (1) | AU2013244859B2 (es) |
BR (1) | BR112014023957B1 (es) |
CA (1) | CA2868611C (es) |
DK (1) | DK2834233T3 (es) |
ES (1) | ES2674945T3 (es) |
FR (1) | FR22C1005I2 (es) |
HK (1) | HK1205115A1 (es) |
HR (1) | HRP20181203T1 (es) |
HU (2) | HUE039290T2 (es) |
IL (1) | IL234663B (es) |
LT (2) | LT2834233T (es) |
MX (1) | MX358429B (es) |
NL (1) | NL301160I2 (es) |
NO (1) | NO2022002I1 (es) |
PL (1) | PL2834233T3 (es) |
PT (1) | PT2834233T (es) |
RU (1) | RU2642065C2 (es) |
SI (1) | SI2834233T1 (es) |
TW (1) | TWI620746B (es) |
WO (1) | WO2013150173A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2015152196A1 (ja) * | 2014-03-31 | 2017-04-13 | 東レ株式会社 | イミダゾリン誘導体及びその医薬用途 |
KR102601972B1 (ko) * | 2015-02-11 | 2023-11-13 | 선오비온 파마슈티컬스 인코포레이티드 | 중추 신경계 질환을 치료하기 위한 1-헤테로사이클릴 이소크로만일 화합물 및 유사체 |
CN105646306B (zh) * | 2015-12-11 | 2020-06-30 | 广东莱佛士制药技术有限公司 | 一种4-甲硫基苯乙酸的制备方法 |
HUE059849T2 (hu) * | 2017-12-01 | 2023-01-28 | Orion Corp | Eljárás 2-(5-metoxi-izokromán-1-il)-4,5-dihidro-1H-imidazol és annak hidrogénszulfát-sója elõállítására |
CN110272407B (zh) * | 2019-07-22 | 2021-02-05 | 河北省农林科学院经济作物研究所 | 一种用于降血压的天然异色满酮类化合物 |
WO2022195174A1 (en) | 2021-03-19 | 2022-09-22 | Orion Corporation | Tasipimidine formulations and use thereof |
CN118632846A (zh) | 2022-01-24 | 2024-09-10 | 奥赖恩公司 | 结构化α-2A肾上腺素受体激动剂的异苯并二氢吡喃-咪唑的新硫酸盐形式 |
WO2023148431A1 (en) | 2022-02-04 | 2023-08-10 | Orion Corporation | Novel salt forms of isochroman-imidazole structured alpha-2a adrenoceptor agonist |
WO2024069050A1 (en) | 2022-09-28 | 2024-04-04 | Orion Corporation | Tasipimidine and cyp2d6 inhibitor combination treatment |
CN117343036A (zh) * | 2023-03-20 | 2024-01-05 | 江苏联环药业股份有限公司 | 异苯并二氢吡喃类化合物及其药物组合物和应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1247008B (de) * | 1965-10-05 | 1967-08-10 | Huels Chemische Werke Ag | Thermoplastische Massen zur Herstellung von vergilbungsfreien antielektrostatischen Formkoerpern aus Polyolefinen |
US3438995A (en) * | 1968-01-08 | 1969-04-15 | Melville Sahyun | Diazaheterocyclic substituted benz-oxaheterocyclic compounds |
EP0166937B1 (en) * | 1984-06-06 | 1991-08-28 | Abbott Laboratories | Adrenergic compounds |
PT1036065E (pt) * | 1997-12-04 | 2004-09-30 | Allergan Inc | Derivados de imidazol substituidos com actividade do tipo agonista nos receptores alfa 2b ou 2b/2c adrenergicos |
FI20000073A0 (fi) * | 2000-01-14 | 2000-01-14 | Orion Yhtymae Oy | Uusia imidatsolijohdannaisia |
JP2009524618A (ja) | 2006-01-27 | 2009-07-02 | エフ.ホフマン−ラ ロシュ アーゲー | Cns障害の処置における2−イミダゾールの使用 |
ATE458732T1 (de) | 2006-01-27 | 2010-03-15 | Hoffmann La Roche | Verwendung von 4-imidazol-derivaten für zns- erkrankungen |
US20080020076A1 (en) * | 2006-07-21 | 2008-01-24 | Khem Jhamandas | Methods and Therapies for Potentiating a Therapeutic Action of an Alpha-2 Adrenergic Receptor Agonist and Inhibiting and/or Reversing Tolerance to Alpha-2 Adrenergic Receptor Agonists |
-
2013
- 2013-03-27 AR ARP130101043 patent/AR090557A1/es active IP Right Grant
- 2013-03-28 KR KR1020147027610A patent/KR102104228B1/ko active IP Right Grant
- 2013-03-28 WO PCT/FI2013/000013 patent/WO2013150173A1/en active Application Filing
- 2013-03-28 ES ES13719297.7T patent/ES2674945T3/es active Active
- 2013-03-28 US US14/389,466 patent/US9249127B2/en active Active
- 2013-03-28 DK DK13719297.7T patent/DK2834233T3/en active
- 2013-03-28 EP EP13719297.7A patent/EP2834233B1/en active Active
- 2013-03-28 CA CA2868611A patent/CA2868611C/en active Active
- 2013-03-28 BR BR112014023957-6A patent/BR112014023957B1/pt active IP Right Grant
- 2013-03-28 CN CN201380018776.XA patent/CN104220437B/zh active Active
- 2013-03-28 RU RU2014144284A patent/RU2642065C2/ru active
- 2013-03-28 JP JP2015503903A patent/JP6427096B2/ja active Active
- 2013-03-28 PT PT137192977T patent/PT2834233T/pt unknown
- 2013-03-28 SI SI201331024T patent/SI2834233T1/en unknown
- 2013-03-28 AU AU2013244859A patent/AU2013244859B2/en active Active
- 2013-03-28 MX MX2014011851A patent/MX358429B/es active IP Right Grant
- 2013-03-28 PL PL13719297T patent/PL2834233T3/pl unknown
- 2013-03-28 HU HUE13719297A patent/HUE039290T2/hu unknown
- 2013-03-28 LT LTEP13719297.7T patent/LT2834233T/lt unknown
- 2013-03-29 TW TW102111298A patent/TWI620746B/zh active
-
2014
- 2014-09-15 IL IL234663A patent/IL234663B/en active IP Right Grant
-
2015
- 2015-06-16 HK HK15105661.0A patent/HK1205115A1/xx unknown
-
2018
- 2018-07-25 HR HRP20181203TT patent/HRP20181203T1/hr unknown
-
2022
- 2022-01-27 NO NO2022002C patent/NO2022002I1/no unknown
- 2022-01-31 NL NL301160C patent/NL301160I2/nl unknown
- 2022-01-31 FR FR22C1005C patent/FR22C1005I2/fr active Active
- 2022-02-02 HU HUS2200005C patent/HUS2200005I1/hu unknown
- 2022-02-03 LT LTPA2022001C patent/LTPA2022001I1/lt unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR090557A1 (es) | DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 | |
AR104884A1 (es) | Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj | |
AR102177A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
PE20151752A1 (es) | Amidas heterociclicas como inhibidores de cinasas | |
AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR103138A1 (es) | Compuestos de heteroarilo como inhibidores de la irak y usos de los mismos | |
AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
AR097866A1 (es) | Derivados de 4-azaindol | |
AR098414A1 (es) | PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e | |
AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
AR090760A1 (es) | Compuestos de benzotiazol y su uso contra el virus de hiv | |
AR094300A1 (es) | Derivados de quinolonas | |
RS54730B1 (sr) | Inhibitori beta sekretaze | |
AR094812A1 (es) | Derivado de piridina monocíclico como inhibidor del fgfr | |
AR093937A1 (es) | Compuestos quimicos | |
AR096153A1 (es) | Derivados de pirrolo[2,3-d]pirimidina | |
AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos | |
AR101359A1 (es) | Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo | |
AR090086A1 (es) | COMPUESTO DE 1H-INDAZOL-3-CARBOXAMIDA COMO INHIBIDORES DE LA GLUCOGENO SINTASA CINASA 3 b | |
AR100724A1 (es) | Derivados de quinolina y su uso en enfermedades neurodegenerativas | |
AR089814A1 (es) | Compuestos que modulan la actividad de los proteasomas | |
AR097894A1 (es) | Inhibidores terapéuticos de cdk8 o uso de los mismos | |
AR098965A1 (es) | Derivados de sulfonamidas tricíclicas | |
AR093128A1 (es) | Inhibidores de la syk |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |